Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Immunomedics Inc (IMMU) Com Stk USD0.01

Sell:$15.01 Buy:$16.11 Change: $0.06 (0.37%)
NASDAQ:0.19%
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
Sell:$15.01
Buy:$16.11
Change: $0.06 (0.37%)
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
Sell:$15.01
Buy:$16.11
Change: $0.06 (0.37%)
Market closed |  Prices as at close on 23 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Contact details

Address:
300 the American Rd
MORRIS PLAINS
07950-2460
United States
Telephone:
+1 (973) 6058200
Website:
https://www.immunomedics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMMU
ISIN:
US4529071080
Market cap:
$3.04 billion
Shares in issue:
191.98 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Behzad Aghazadeh
    Executive Chairman of the Board
  • Usama Malik
    Chief Financial Officer
  • Kurt Andrews
    Chief Human Resource Officer
  • Morris Rosenberg
    Chief Technology Officer
  • William Fricker
    Principal Accounting Officer
  • Jared Freedberg
    General Counsel, Corporate Secretary
  • Scott Canute
    Executive Director
  • Bryan Ball
    Chief Quality Officer
  • Brendan Delaney
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.